

IN THE CLAIMS:

Please delete the current version of claim 3 and insert the amended version of claim 3 as follows:

3. (Twice Amended) Medicament according to claim 1, wherein the polycationic peptide or protein is selected from the group consisting essentially of:


- human lactoferrin, bovine lactoferrin, lactoferrin, conalbumin (ovotransferrin), the polycationic peptides occurring in these proteins, hydrolysates of lactoferrin, and cation rich peptides originating from lactoferrin;

- poly-peptide having an amino acid sequence selected from the following sequences (1) – (15), or derivatives thereof having an amide at the carboxy end thereof:

- 
- (1) Arg-Trp-Gln-Trp-Arg; (SEQ ID NO: 1)
 - (2) Arg-Arg-Gln-Trp-Arg; (SEQ ID NO: 2)
 - (3) Lys-Val-Ser-Trp-Arg; (SEQ ID NO: 3)
 - (4) Arg-Asn-Met-Arg-Lys; (SEQ ID NO: 4)
 - (5) Arg-Trp-Gln-Glu-Lys; (SEQ ID NO: 5)
 - (6) Arg-Arg-Trp-Gln-Trp-Arg; (SEQ ID NO: 6)
 - (7) Arg-Arg-Arg-Gln-Trp-Arg; (SEQ ID NO: 7)
 - (8) Lys-Thr-Val-Ser-Trp-Arg; (SEQ ID NO: 8)
 - (9) Lys-Arg-Asn-Met-Arg-Lys; (SEQ ID NO: 9)
 - (10) Arg-Trp-Gln-Glu-Met-Lys; (SEQ ID NO: 10)
 - (11) Lys-Thr-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys; (SEQ ID NO: 11)
 - (12) Lys-Ser-Arg-Arg-Arg-Gln-Trp-Arg-Met-Lys-Lys; (SEQ ID NO: 12)
 - (13) Lys-Thr-Val-Ser-Trp-Gln-Thr-Tyr-Met-Lys-Lys; (SEQ ID NO: 13)
 - (14) Lys-Thr-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys; (SEQ ID NO: 14)


(15) Lys-Thr-Leu-Arg-Trp-Gln-Asn-Glu-Met-Arg-Lys; (SEQ ID NO: 15)

a peptide containing one of the following amino acid sequences (a), (b), (c), or (d):


Lys-Cys-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-Gly-Ala-

Pro-Ser-Ile-Thr-Cys-Val-; (a) (SEQ ID NO: 16)

-Lys-Cys*-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-Gly-Ala-Pro-Ser-Ile-Thr-Cys*-Val; (b) (SEQ ID NO: 17)


Lys-Cys-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-

Pro-Pro-Val-Ser-Cys-Ile-; (c) (SEQ ID NO: 18)

-Lys-Cys*-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Gly-Pro-Pro-Val-Ser-Cys*-Ile; (b) (SEQ ID NO: 19)

where Cys* represents cysteine in which the thiol group is blocked in order to prevent disulfide bond formation; and mixtures thereof and pharmaceutically and sitologically acceptable salts thereof;

- a peptide consisting of one of the following specific amino acid sequences (a)-(l) or derivatives thereof having an amide at the carboxy end thereof:

(a) Phe-Gln-Trp-Gln-Arg-Asn (SEQ ID NO: 20)

(b) Phe-Gln-Trp-Gln-Arg (SEQ ID NO: 21)

(c) Gln-Trp-Gln-Arg (SEQ ID NO: 22)

(d) Trp-Gln-Arg

(e) Arg-Arg-Trp-Gln-Trp (SEQ ID NO: 23)

(f) Arg-Arg-Trp-Gln (SEQ ID NO: 24)

(g) Trp-Gln-Trp-Arg (SEQ ID NO: 25)

(h) Gln-Trp-Arg

(i) Leu-Arg-Trp-Gln-Asn-Asp (SEQ ID NO: 26)

(j) Leu-Arg-Trp-Gln-Asn (SEQ ID NO: 27)

(k) Leu-Arg-Trp-Gln (SEQ ID NO: 28)

(l) Arg-Trp-Gln

and lactoferrin hydrolyzate for the manufacture of antibacterial agent, and chemical derivatives thereof, wherein by the derivatives, the polarity of the amino group of the amino acid residue constituting the protein is chemically modified into a negative moiety;

- polycations belonging to the family of α or β defensins, such as magainins, cecropins type A or B, protegrins, indolicidin analogs, polycations isolatable from insects, and histones:

- mixtures thereof; and

-pharmaceutically and cytologically acceptable salts of this group.